Calpe-Berdiel Laura, Escolà-Gil Joan Carles, Blanco-Vaca Francisco
Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Atherosclerosis. 2009 Mar;203(1):18-31. doi: 10.1016/j.atherosclerosis.2008.06.026. Epub 2008 Jul 6.
Plant sterols and stanols (phytosterols/phytostanols) are known to reduce serum low-density lipoprotein (LDL)-cholesterol level, and food products containing these plant compounds are widely used as a therapeutic dietary option to reduce plasma cholesterol and atherosclerotic risk. The cholesterol-lowering action of phytosterols/phytostanols is thought to occur, at least in part, through competition with dietary and biliary cholesterol for intestinal absorption in mixed micelles. However, recent evidence suggests that phytosterols/phytostanols may regulate proteins implicated in cholesterol metabolism both in enterocytes and hepatocytes. Important advances in the understanding of intestinal sterol absorption have provided potential molecular targets of phytosterols. An increased activity of ATP-binding cassette transporter A1 (ABCA1) and ABCG5/G8 heterodimer has been proposed as a mechanism underlying the hypocholesterolaemic effect of phytosterols. Conclusive studies using ABCA1 and ABCG5/G8-deficient mice have demonstrated that the phytosterol-mediated inhibition of intestinal cholesterol absorption is independent of these ATP-binding cassette (ABC) transporters. Other reports have proposed a phytosterol/phytostanol action on cholesterol esterification and lipoprotein assembly, cholesterol synthesis and apolipoprotein (apo) B100-containing lipoprotein removal. The accumulation of phytosterols in ABCG5/G8-deficient mice, which develop features of human sitosterolaemia, disrupts cholesterol homeostasis by affecting sterol regulatory element-binding protein (SREBP)-2 processing and liver X receptor (LXR) regulatory pathways. This article reviews the progress to date in studying these effects of phytosterols/phytostanols and the molecular mechanisms involved.
植物甾醇和甾烷醇(植物固醇/植物甾烷醇)已知可降低血清低密度脂蛋白(LDL)胆固醇水平,含有这些植物化合物的食品被广泛用作降低血浆胆固醇和动脉粥样硬化风险的治疗性饮食选择。植物固醇/植物甾烷醇的降胆固醇作用被认为至少部分是通过与膳食和胆汁胆固醇竞争混合微团中的肠道吸收来实现的。然而,最近的证据表明,植物固醇/植物甾烷醇可能调节肠细胞和肝细胞中与胆固醇代谢相关的蛋白质。在理解肠道甾醇吸收方面的重要进展为植物固醇提供了潜在的分子靶点。ATP结合盒转运蛋白A1(ABCA1)和ABCG5/G8异二聚体活性增加被认为是植物固醇降胆固醇作用的潜在机制。使用ABCA1和ABCG5/G8缺陷小鼠的确定性研究表明,植物甾醇介导的肠道胆固醇吸收抑制与这些ATP结合盒(ABC)转运蛋白无关。其他报告提出了植物固醇/植物甾烷醇对胆固醇酯化和脂蛋白组装、胆固醇合成以及含载脂蛋白(apo)B100的脂蛋白清除的作用。在出现人类谷甾醇血症特征的ABCG5/G8缺陷小鼠中,植物甾醇的积累通过影响甾醇调节元件结合蛋白(SREBP)-2的加工和肝X受体(LXR)调节途径破坏了胆固醇稳态。本文综述了迄今为止在研究植物固醇/植物甾烷醇的这些作用及其涉及的分子机制方面取得的进展。